SCHEMBL273472

SCHEMBL273472

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1ccc(Cl)c(C(F)(F)F)c1)c1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.46
RAB9A P51151 11/20 0.43
MAPT P10636 11/20 0.43
NPC1 O15118 9/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
PKM P14618 2/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
GAA P10253 1/20 0.43
GFER P55789 1/20 0.43
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266460 1.00 POLB (0.46) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL267373 0.85 NPC1 (0.48) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL273687 0.85 GRM4 (0.53) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL273927 0.85 NPC1 (0.48) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL267372 0.85 NPC1 (0.48) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL266825 0.85 GRM4 (0.53) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL273287 0.84 MAPT (0.56) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL269023 0.84 MAPT (0.56) POLBRAB9AMAPTNPC1SMN1; SMN2
SCHEMBL273628 0.83 NPSR1 (0.52) RAB9AMAPTNPC1SMN1; SMN2PKM
SCHEMBL268798 0.83 NPSR1 (0.52) RAB9AMAPTNPC1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 POLB 3761/4885RAB9A 1362/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.